Skip to main content
Interview with the Innovators

Broadening the Variety of Candidate Therapies for R/R Follicular Lymphoma Allows Optimal Personalized Rx Choice, While Patient-Directed Education Helps Attain Greatest Clinical Benefit

Tycel J. Phillips, MD
Clinical Associate Professor
University of Michigan Rogel Cancer Center
Ann Arbor, MI
Peg Rummel, MHA, RN, OCN, NE-BC
Oncology Nurse Navigator
Hematology/Head & Neck Clinical Services
University of Pennsylvania Abramson Cancer Center
Philadelphia, PA
Andrew D. Zelenetz, MD, PhD
Medical Oncologist and Medical Director
Quality Informatics, Memorial Sloan Kettering Cancer Center Professor of Medicine, Weill Cornell Medical College Chair, Lymphoma Research Foundation, Scientific Advisory Board
New York, NY

Dr Tycel Phillips debates the importance of having more effective and better tolerated treatments for patients who present with recurrent or treatment-refractory follicular lymphoma (FL). Often, these patients have undergone more than 1 or 2 previous lines of therapy and cannot tolerate all types of therapies within the gamut of potential choices. In such patients, it is desirable to have flexibility in the choice of a therapy regimen, for example, one that is chemotherapy-free. Ms Peg Rummel commented that oncology nurses and nurse navigators are paramount in educating the patients and their caregivers around all aspects of therapy, and help alleviate psychological stress, anxiety, and fear of the unknown by explaining to patients with relapsed or refractory FL the various paths along their therapeutic journey.

Supported by

Related Items